other material
confidence high
sentiment positive
materiality 0.65
Exelixis settles CABOMETYX patent litigation; Cipla generic launch from Jan 1, 2031
EXELIXIS, INC.
- Settlement with Cipla resolves two Hatch-Waxman patent suits over CABOMETYX (cabozantinib).
- Cipla receives license to market generic CABOMETYX in US starting January 1, 2031, if FDA approved.
- All ongoing Delaware district court litigation will be dismissed pending FTC review.
- Agreement confidential and subject to review by FTC and DOJ.